![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants De Novo Approval for Multiple Sclerosis Gait Deficit Treatment
FDA Grants De Novo Approval for Multiple Sclerosis Gait Deficit Treatment
![FDA Grants](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA-grants.gif?t=1616791818&width=430)
The FDA has given Helius Medical’s Portable Neuromodulation Stimulator (PoNS) device De Novo authorization for short-term treatment of gait deficit due to multiple sclerosis.
The prescription-only device delivers neuromuscular electrical stimulation to the dorsal surface of the patient’s tongue to treat gait deficit caused by mild-to-moderate MS symptoms. It comes with a wearable mouthpiece and accompanying controller.
The system is now cleared for use in patients 22 years and older, but only as an adjunct to a supervised therapeutic exercise program.
Upcoming Events
-
21Oct